Emergent BioSolutions Downgraded as Narcan Sales Wane and Debt Remains a Concern

On September 6, 2026, Emergent BioSolutions Inc. (NYSE: EBS) slipped from a Buy to a Hold rating when Seeking Alpha anal...

Read story →